Clinical Trial Update: Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal [Phase 1]

View source ↗

Summary

A phase 1 study evaluating tumor cell vaccines with ISCOMATRIX adjuvant and chemotherapy after tumor removal in sarcoma and melanoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Malignancies
• Melanoma
• Pleural Malignancy
• Sarcoma

Drugs mentioned

• ISCOMATRIX (ISCOMATRIX adjuvant)
• Tumor Cell Vaccine

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Sarcoma, Melanoma | Phase 1 | Status: TERMINATED